Agenus Inc. Debt/Assets

Debt/Assets of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Debt/Assets for the quarter ending June 29, 2020 was 10.95% (a 48.98% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Assets decreased by -13.37%
  • Annual Debt/Assets for 2019 was 9.03% (a -7.76% decrease from previous year)
  • Annual Debt/Assets for 2018 was 9.79% (a -91.69% decrease from previous year)
  • Annual Debt/Assets for 2017 was 117.79% (a 41.49% increase from previous year)
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of Agenus Inc.

Most recent Debt/Assetsof AGEN including historical data for past 10 years.

Interactive Chart of Debt/Assets of Agenus Inc.

Agenus Inc. Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 10.95% 7.35%
2019 9.03% 12.64% 10.14% 7.88% 9.03%
2018 9.79% 10.12% 9.89% 9.87% 9.79%
2017 117.79% 95.97% 78.57% 66.07% 117.79%
2016 83.25% 72.3% 62.24% 53.5% 83.25%
2015 47.26% 45.63% 6.34% 0.36% 47.26%
2014 8.09% 7.66% 7.41% 3.77% 8.09%
2013 25.45% 8.65% 11.39% 144.55% 25.45%
2012 123.34% 110.03% 105.63% 100.07% 123.34%
2011 165.77% 127.69% 137.66% 109.24% 165.77%
2010 110.64% 135.58% 117.18% 127.66% 110.64%
2009 108.21% 93.69% 108.21%

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Further, it develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bifunctional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. Additionally, the company engages in the development INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390 – an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.